. These doses could easily be achieved at midday in temperate latitudes under summer sun and were less than that required to achieve 50% suppression in the most sensitive mice in Noonan's studies. Hence, the responses of mice and humans to UVRinduced suppression of CH are quantitatively similar (Table 1 ). Dr. Selgrade described a parallelogram model ( Fig. 1 ) that has been used to make comparisons between effects in laboratory rodents and humans, and between deficits in immune function and increased susceptibility to disease (5) . In such models, dose-response data from Drs. Noonan and Assaf would correspond to the upper corners of the parallelogram. Dose-response data on host resistance to infection in mice and the potential for assessing vaccine effectiveness in humans presented in session two would correspond to the lower corners. Quantitative comparisons could then be made between the corners of the parallelogram, which would indicate how well CHS predicts effects on response to infectious disease and how well mouse data predicts human effects.
Session 2: Potential impact of UVR on infectious disease and vaccine effectiveness. Dr. Jeevan reviewed studies in which UVR exposure increased the incidence and/or severity of infection in mice challenged with viral, parasitic, fungal, and bacterial agents. She presented data with Mycobacterium bovis BCG (the vaccine strain for tuberculosis) and M. lepraemurium (a mouse leprosy model). The UVR dose required for 50% suppression of the DTH response to these two agents (Table 1 ) resulted in approximately a threefold increase in the number of BCG bacteria in spleen and lymph nodes of infected mice (6) . Dr. van Loveren described similar studies in rats in which there was a strong relationship between suppression of the in vitro lymphoproliferative response to bacterial antigen following in vivo UVR exposure and increased susceptibility to challenge with bacteria. Also, he reported a 3.8-fold difference in the dose required to suppress the skin-mixed lymphocyte response by 50% in humans and rats and indicated that his data could be applied in a parallelogram model to predict effects on resistance to bacterial infection in humans. (Table 1 ) (7). Dr. Ward described three opportunities for field studies to assess effects of UVR exposure on vaccine effectiveness in humans. First, vacci-nation with BCG is about 50% effective against tuberculosis and is given to most children in developing nations shordy after birth. In some of these same nations, hyperbilirubinemia in newborns is treated by graded solar exposure (containing UVR), usually before BCG vaccination. Children without hyperbilirubinemia are generally protected from the sun. Hence, comparison of subsequent responses to BCG in these two populations would provide an indication of the effect of UVR on vaccineinduced immunity. Second, a study of the influence of season on cellular responses to measles vaccine presents another opportunity when conducted in an area with dramatic seasonal differences in climatic conditions (e.g., Lima, Peru). Third, a comparison of hepatitis B vaccine-induced responses after short-term travel from temperate regions (e.g., Montreal) to the tropics for beach holidays versus other types of low-UVR exposure travel is also feasible. Drs. Duncan and Regan described personal dosimeters, polysulphone badges (8) , and badges consisting of dried Lambda DNA between layers of ACLAR film (9, respectively, which could be used along with radiometric measures of temic autoimmune disease such as SLE appears to be mediated by Th2 cells, in contrast to organ-specific autoimmune diseases (e.g., insulin-dependent diabetes mellitus), where Th 1 cells appear to be more important. Hence, UVR has the potential to affect autoimmune diseases in either an adverse or beneficial fashion depending on the disease.
Summary of research needs identified.
The group was unanimous in giving highest priority to studying the effects of UVR on vaccine effectiveness in humans. All three studies presented by Dr. Ward would be valuable. However, the proposed studies were ranked in priority as follows 1) BCG, 2) measles, and 3) hepatitis. There was consensus that these studies should incorporate the use of both personal dosimeters and radiometric measurements of ambient UVR in order to obtain dose-response information.
Information on the effects of UVR should be expanded beyond DTH Finally, UVR appears to favor Th2 responses, suggesting that risks associated with common allergies and asthma may be increased by UVR exposure. This possibility has not been explored. Also, although UVR is known to exacerbate certain autoimmune diseases, the link with UVRmodulation of the immune system has not been made. The group felt that these risks could best be addressed using animal models. Should these studies suggest that UVR can enhance allergic or autoimmune disease, then human studies could be planned to assess these risks.
